Skip to main content
SpringerLink
Log in

Prescribing metformin in type 2 diabetes with a contraindication: prevalence and outcome

  • Research Article
  • Published:
Pharmacy World & Science Aims and scope Submit manuscript

Abstract

Objectives (1) To determine the prevalence of metformin prescribing in type 2 diabetes with a contraindication and (2) to explore whether metformin use on top of contraindications modified the risks of lactic acidosis, hospitalization, and death in type 2 diabetes. Setting Ambulatory diabetic clinics of the secondary-level care General Hospital of Hatyai district, Songkhla province, South Thailand. Method A cross-sectional study was carried out for the objective (1). A retrospective cohort study was applied to meet the objective (2). Out-patient medical case notes were reviewed for metformin use, number of hospitalizations, lactic acidosis cases, death cases, and the presence of contraindications, which were limited to: (1) chronic renal impairments, (2) chronic liver diseases, and (3) cardiac failure. Only documented diagnoses of the above conditions were counted. Main outcome measure The prevalence of metformin use in type 2 diabetes with a contraindication; odds ratios (ORs) of the occurrences of lactic acidosis, hospitalization, and death in type 2 diabetes with a contraindication modified by metformin use. Results A total of 1,630 type 2 diabetic outpatients were identified; 19.3% (315/1,630) had at least one contraindication to metformin use, with chronic renal impairment being the most frequent risk (78%, 246/315). Of those with a contraindication, 84.4% (266/315) were metformin users. Compared to non-metformin users, there were no significant differences in the number of hospitalizations and deaths. No cases of lactic acidosis were evident. Metformin use in the presence of contraindications did not affect the risks of hospitalization (OR 0.73, 95% confidence interval [CI] 0.38–1.4, P = 0.34) or death (OR 0.58, 95% CI 0.11–3.15, P = 0.53). Other patient factors, such as the female gender or having diabetes-related complications, had significant influences on both outcomes. Conclusion The prevalence of type 2 diabetes receiving metformin despite having a contraindication was over 80%. However, metformin use in such conditions did not appear to increase the risks of hospitalization and death. No lactic acidosis was reported. Other patient factors than metformin affect the risks of hospitalization and death.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–65. Erratum: p 1558.

    Article  Google Scholar 

  2. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006;29:1963–72.

    Article  PubMed  Google Scholar 

  3. Selby JV, Ettinger B, Swain BE, Brown JB. First 20 months’ experience with use of metformin for type 2 diabetes in a large health maintenance organization. Diabetes Care. 1999;22:38–44.

    Article  CAS  PubMed  Google Scholar 

  4. Cryer DR, Nicholas SP, Henry DH, Mills DJ, Stadel BV. Comparative outcomes study of metformin intervention versus conventional approach. The COSMIC Approach Study. Diabetes Care. 2005;28:539–43.

    Article  CAS  PubMed  Google Scholar 

  5. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med. 2003;163:2594–602.

    Article  PubMed  Google Scholar 

  6. Salpeter S, Greyber E, Pasternak G, Salpeter E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2006, Issue 1. Art. No.:CD002967. doi:10.1002/14651858.CD002967.

  7. Holstein A, Stumvoll M. Contraindications can damage your health—is metformin a case in point? Diabetologia. 2005;48:2454–9.

    Article  CAS  PubMed  Google Scholar 

  8. Tahrani AA, Varughese GI, Scarpello JH, Hanna FWF. Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated? BMJ. 2007;335:508–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Inzucchi SE, Masoudi FA, McGuire DK. Metformin in heart failure [observations]. Diabetes Care. 2007;30:e129.

    Article  PubMed  Google Scholar 

  10. Roberts F, Ryan GJ. The safety of metformin in heart failure. Ann Pharmacother. 2007;41:642–6.

    Article  CAS  PubMed  Google Scholar 

  11. Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care. 2005;28:2345–51.

    Article  CAS  PubMed  Google Scholar 

  12. Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation. 2005;111:583–90.

    Article  CAS  PubMed  Google Scholar 

  13. Lalau JD, Race JM. Lactic acidosis in metformin therapy: searching for a link with metformin in reports of ‘metformin-associated lactic acidosis’. Diabetes Obes Metab. 2001;3:195–201.

    Article  CAS  PubMed  Google Scholar 

  14. Stades AME, Heikens JT, Erkelens DW, Holleman F, Hoekstra JBL. Metformin and lactic acidosis: cause or coincidence? A review of case reports. J Intern Med. 2004;255:179–87.

    Article  CAS  PubMed  Google Scholar 

  15. Ellis AK, Iliescu EA. Metformin-associated lactic acidosis in a low risk patient. Can J Clin Pharmacol. 2001;8:104–6.

    CAS  PubMed  Google Scholar 

  16. Chu CK, Chang YT, Lee BJ, Hu SY, Hu WH, Yang DY. Metformin-associated lactic acidosis and acute renal failure in a type 2 diabetic patient. J Chin Med Assoc. 2003;66:505–8.

    PubMed  Google Scholar 

  17. Brassøe R, Elkmann T, Hempel M, Gravholt CH. Fulminant lactic acidosis in two patients with type 2 diabetes treated with metformin. Diabet Med. 2005;22:1451–3.

    Article  PubMed  Google Scholar 

  18. DePalo VA, Mailer K, Yoburn D, Crausman RS. Lactic acidosis. Lactic acidosis associated with metformin use in treatment of type 2 diabetes mellitus. Geriatrics. 2005;60:36, 39–41.

    PubMed  Google Scholar 

  19. CMPMedica. MIMS drug information system, Thailand. 2008. Available online at: http://www.mims.com. Accessed 10 Nov 2008.

  20. Sweileh WM. Contraindications to metformin therapy among patients with type 2 diabetes mellitus. Pharm World Sci. 2007;29:587–92.

    Article  CAS  PubMed  Google Scholar 

  21. Horlen C, Malone R, Bryant B, Dennis B, Carey T, Pignone M, et al. Frequency of inappropriate metformin prescriptions. JAMA. 2002;287:2504–5.

    Article  PubMed  Google Scholar 

  22. Rachmani R, Slavachevski I, Levi Z, Zadok B, Kedar Y, Ravid M. Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications. Eur J Intern Med. 2002;13:428.

    Article  CAS  PubMed  Google Scholar 

  23. Lacy CF, Armstrong LL, Goldman MP, Lance LL. Drug Information Handbook. A comprehensive resource for all clinicians and healthcare professionals. 2006–2007. 14th ed. Hudson: Lexi-Comp Inc.; 2006. p. 1091.

    Google Scholar 

  24. Millican S, Cottrell N, Green B. Do risk factors for lactic acidosis influence dosing of metformin? J Clin Pharm Ther. 2004;29:449–54.

    Article  CAS  PubMed  Google Scholar 

  25. Emslie-Smith AM, Boyle DIR, Evans JMM, Sullivan F, Morris AD; DARTS/MEMO Collaboration. Contraindications to metformin therapy in patients with type 2 diabetes—a population-based study of adherence to prescribing guidelines. Diabet Med 2001;18:483–8.

    Article  CAS  PubMed  Google Scholar 

  26. Calabrese AT, Coley KC, DaPos SV, Swanson D, Rao RH. Evaluation of prescribing practices: risk of lactic acidosis with metformin therapy. Arch Intern Med. 2002;162:434–7.

    Article  PubMed  Google Scholar 

  27. Kosachunhanun N, Benjasuratwong Y, Mongkolsomlit S, Rawdaree P, Plengvidhya N, Leelawatana R, et al. Thailand Diabetes Registry Project: glycemic control in Thai type 2 diabetes and its relation to hypoglycemic agent usage. J Med Assoc Thai. 2006;89(Suppl 1):S66–71.

    PubMed  Google Scholar 

Download references

Acknowledgements

We are grateful to Miss Jaruwee Kanjanakeereethamrong of the Department of Pharmacy at Songkhla General Hospital for coordinating the data collection. Our thanks are also extended to Mr. Murray John McMurdo for the language proofreading.

Funding

This research project was supported by the annual research grant from the Faculty of Pharmaceutical Sciences and Prince of Songkla University.

Conflict of interest statement

None.

Author information

Authors and Affiliations

  1. Faculty of Pharmaceutical Sciences, Prince of Songkla University, Hatyai, Songkhla, 90112, Thailand

    Juraporn Pongwecharak, Nawatsanan Tengmeesri, Nongluck Malanusorn, Matshamon Panthong & Nantida Pawangkapin

Authors
  1. Juraporn Pongwecharak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nawatsanan Tengmeesri
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nongluck Malanusorn
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Matshamon Panthong
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nantida Pawangkapin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Juraporn Pongwecharak.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pongwecharak, J., Tengmeesri, N., Malanusorn, N. et al. Prescribing metformin in type 2 diabetes with a contraindication: prevalence and outcome. Pharm World Sci 31, 481–486 (2009). https://doi.org/10.1007/s11096-009-9303-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11096-009-9303-2

Keywords

Search

Navigation